In-Depth

The In-Depth page consists of Insight Articles, Commentaries, C-level Q&As, Discussion Group Reports, and Survey Reports.

Insight Article
In this Insight Article, we explore the future possibilities, challenges, and solutions in peptide purification and the delivery of precision medicine for immunotherapy.
By Tia Byer |
14 January 2022
Peptides
Commentary
Christine Rothe, Vice President of Early-Stage-Project Leadership and Data Science at Pieris Pharmaceuticals, presents a case study on Anticalin-antibody fusions for IO.
By Tia Byer |
08 December 2021
Proteins & Antibodies
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our October Discussion Group addressing ‘Analytical Method Development for Biotherapeutics’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
By Tia Byer |
09 November 2021
Biologics Analysis
Commentary
Can biparatopic antibody-drug conjugates enhance cellular trafficking to cancerous tumours? William Olson of Regeneron finds out.
By Tia Byer |
01 November 2021
Proteins & Antibodies
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. The first of its kind, our September Discussion Group addressing ‘Antibody Discovery, Optimisation & Engineering’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
By Tia Byer |
13 October 2021
Proteins & Antibodies
Commentary
Can AI-driven peptide purification advance the therapeutic capabilities of peptide drugs? Principal Scientist at Novo Nordisk, Jacob Kofoed takes us through their high-throughput peptide synthesis and purification platform and its promise to do just that.
By Tia Byer |
01 October 2021
Peptides
Insight Article
At 2021’s Biologics Europe: Online, we sat down with an advisory group of leading industry experts to hear their thoughts on the state of the Biologic drug industry and the potential of Biotherapeutic manufacturing. Biologics engineering is a rapidly evolving field, and 2022 looks to be a year of exciting technological and strategy breakthroughs.
By Tia Byer |
20 August 2021
Proteins & Antibodies
Insight Article
2020 and 2021 have been dominated by headlines about the COVID inoculation programme and its tremendous success. But what’s next for the vaccine?
By Tia Byer |
16 August 2021
Vaccines
Insight Article
Andre Cobb, Senior Lecture in Organic Chemistry, King’s College London. Date of Congress: 27th - 29th April 2020
02 January 2020
Peptides
Insight Article
Dr. Philip Webber, Patent Attorney, Dehns Patent and Trade Mark Attorneys
16 April 2018
Biosimilars & Biobetters
Insight Article
Janice M. Reichert, PH.D., Executive Director, The Antibody Society& Editor-in-Chief, mAbs
16 April 2018
Proteins & Antibodies
Insight Article
Gregory J. Glover, Attorney at Law, Pharmaceutical Law Group PC
16 April 2018
Biosimilars & Biobetters
Advertisement

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Biologics

Submit your details to receive the monthly newsletter & to be kept up to date about relevant events, monthly discussion groups and portal membership offers. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.